Abond CRO Announces That Mr. Zoran Antonijevic Is Their New Vice President, Statistical Consulting

ALLENDALE, Mich.--(BUSINESS WIRE)--Dr. Phil Doren, Chief Executive Officer and Vice President, is pleased to announced today that Zoran Antonijevic is the Vice President, Statistical Consulting at Abond CRO Inc. "With this single appointment, we have greatly strengthened our capability to address customers' needs in statistical consulting for drug development," Doren said.

Mr. Antonijevic is an industry thought leader with cutting edge knowledge of innovative methods and strategies including adaptive design, platform trials, and program/portfolio optimization. He has extensive experience with drug development, department development and decision making. He is the long-time Chair and leader of the DIA Adaptive Design Scientific Working Group. His background covers numerous therapeutic areas and his professional strengths include development strategy, thought leadership and vision, consulting, program and portfolio level optimization, master protocols, decision science, analytics, due diligence, regulatory, department vision, processes and metrics and talent identification.

More on Amzeal News

• Now Available at NeoMetrix Technologies, the NEW peel 2S
• ConvergeOne and Evolve IP Enter Strategic Hospitality Partnership
• Alliance Technologies Launches Alliance University
• Home2 Suites by Hilton Tucson Airport Celebrates Topping Off - Tucson's Newest Extended-Stay Hotel
• Truthset and the ANA AIMM Release First of its Kind Multicultural Online Data Benchmarks

Prior to coming to Abond CRO, Mr. Antonijevic's CRO experience included leading Biometrics, where he managed all biostatistics, programming, data management and medical writing activities, and previously he was Senior Director of Strategy, and the Senior Director/Director, Center for Statistics in Drug Development Innovation.

His experience at major pharmaceutical companies includes Innovative & Adaptive Design Executive Director and Head of Development Design Center, and, very early in his career, was a Principal Statistician.

Mr. Antonijevic formed his own consulting company and while doing that work, served as Chief Scientific Officer for a global health firm specializing in highly-efficient clinical study designs and biostatistical methods. He began his career at the Harvard School of Public Health, AIDS Clinical Trials Group (ACTG).

"Abond CRO is excited to have Zoran join our company. His leadership, experience and amazing technical expertise greatly enhances our foundational and long-standing tradition of excellent direction and support in statistical consulting for our customers," Doren added.

More on Amzeal News

• Julia Hair Tax Refund Season Flash Sale Week With Buy Now Pay Later
• The Best Virgin Hair Vendors 2021
• ACS Lawyer In Brooklyn Announces Dismissal of OCFS Case
• Infosec's Choose Your Own Adventure® Security Awareness Games win Achievement of the Year in Video
• Liquid Core® Gum Company announces TDA Boulder Creative Director Jonathan Schoenberg has joined its Advisory Board

About Abond CRO Inc. (www.abondcro.com)

Abond is a full-service clinical research organization dedicated to providing specialized clinical research support for the pharmaceutical and medical device industries since its founding in 1974 (incorporation in 1985). They deliver everything you'd expect from a full-service CRO — consulting, clinical operations, data management, statistical analysis — and a few things that set them apart: honesty, focus, and responsibility. Abond works with small startup organizations to established pharmaceutical and medical device leaders around the world.

---

Show All News | Report Violation